SuperGen shares slide on late-stage Dacogen failure
Shares of SuperGen took a dive this morning after the company revealed that Dacogen failed a late-stage trial for the bone marrow disease MDS. Researchers say the drug failed to improve the median survival rate of patients when compared to a group receiving best standard of care. A total of 233 patients volunteered for the trial.
Dacogen is partnered with MGI Pharma, which is now owned by Japan's Eisai. Analysts say Dacogen's failure is a plus for Celgene's Vidaza, which is being relaunched this fall. Dacogen was approved in 2006.
- check out SuperGen's release
- read the AP report
Related Articles:
FDA gives Dacogen orphan drug status
FDA approves Dacogen for MDS
J&J unit gains Dacogen rights in $80M deal
Be the first to comment
Comments
Post new comment
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
